MX1 and COVID-19: In addition, there was a significantly shorter time between onset of symptoms and presentation in patients with high MxA level, and a lower chance to have detectable IgG antibodies against SARS-CoV-2, which might indicate that these patients had a quicker deterioration in early inflammatory phase of COVID-19.